Embecta Stock Plunges 57% on Guidance Cut, Class Action Filed

Embecta Corp. (NASDAQ: EMBC) lost more than half its market value in a single trading session after the company slashed its full-year revenue forecast and reported earnings that missed its own targets by a wide margin. The stock fell $5.35 to close at $3.90 on May 6, a 57.8% decline, following the after-hours earnings release the prior day.

The company reported adjusted earnings per share of $0.27 for the quarter ended March 31, down from $0.70 a year earlier. Revenue guidance for fiscal 2026 was cut to a range of $1.015 billion to $1.035 billion, compared with the previous range of $1.071 billion to $1.093 billion.

“We were disappointed with our second quarter results as they were significantly below our expectations,” Embecta said in the earnings release.

A securities class action lawsuit filed in federal court alleges that the company and its management knew or should have known about the deteriorating sales trends before telling investors otherwise. The complaint, filed by Kaplan Fox & Kilsheimer, claims that management reaffirmed the original guidance during the first-quarter 2026 earnings call even as segment weakness, particularly in the U.S. pen needle market, was building.

According to the complaint, the defendants “knew or recklessly disregarded that segment weakness, especially in the United States pen needle market, was likely to disrupt the Company’s original revenue guidance and second quarter 2026 results.”

Investors who purchased Embecta securities between Nov. 25, 2025 and May 4, 2026–the proposed class period–are covered by the lawsuit. The deadline to move the court for appointment as lead plaintiff is Aug. 17, 2026. Investors who suffered losses do not need to serve as lead plaintiff to share in any potential recovery.

Embecta, a medical device company focused on diabetes management, was spun off from Becton Dickinson in 2022. Its products include insulin syringes and pen needles. The stock had already been under pressure earlier in 2026 before the May guidance revision.

Kaplan Fox, a plaintiffs’ securities litigation firm founded in 1956, says it has recovered more than $10 billion for clients in securities, antitrust and consumer protection cases. The firm has offices in New York, Oakland, Los Angeles, Chicago and New Jersey. It has served as lead or co-lead counsel in landmark cases including a $2.425 billion recovery for Bank of America shareholders and an $800 million recovery for the Arkansas Teacher Retirement System against Allianz Global Investors.

The company did not respond to a request for comment.